Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine

References

• Turton, K.; Chaddock, J.A.; Acharya, K.R. Botulinum and tetanus neurotoxtins: Structure, function and therapeutic utility. Trends Biochem Sci. 2002, 27:552–558.
   PubMed Web of Science ®Google Scholar
• Schiavo, G..; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000, 80:717–766.
   PubMed Web of Science ®Google Scholar
• Middlebrook, J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev. 2005, 57:1415–1423.
   Google Scholar
• Byrne, M.P.; Smith, L.A. Development of vaccines for prevention of botulism. Biochimie. 2000, 82:955–966.
   PubMed Web of Science ®Google Scholar
• LaPenotiere, H.F.; Clayton, M.A.; Middlebrook, J.L. Expression of a large nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon. 1995, 33:1383–1386.
   PubMed Web of Science ®Google Scholar
• Clayton, M.A.; Clayton, J.M.; Brown, D.R.; Middlebrook, J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun. 1995, 63:2728–2742.
   Web of Science ®Google Scholar
• Holley, J.L.; Elmore, M.; Mauchline, M.; Minton, N.; Titball, R.W. Cloning, expression and evaluation sub-unit vaccine against clostridium type F toxin. Vaccine. 2001, 19:288–297.
   Web of Science ®Google Scholar
• Woodward, L.A.; Arimitsu, H.; Hirst, R.; Oguma, K. Expression of Hc subunits from clostridium botulinum type C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun. 2003, 71:2941–2944.
   PubMed Web of Science ®Google Scholar
• Tavallaie, M.; Chenal, A.; Gillet, D.; Pereira, Y.; Manich, M.; Gibert, M.; Raffestin, S.; Popoff, M.R.; Marvaud, J.C. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett. 2004, 572:299–306.
   Google Scholar
• Baldwin, M.R.; Tepp, W.H.; Pier, C.L.; Bradshaw, M.; Ho, M.; Wilson, B.A.; Fritz, R.B.; Johnson, E.A.; Barbieri, J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun. 2005, 73:6998–7005.
   PubMed Web of Science ®Google Scholar
• Lee, J.C.; Hwang, H.J.; Sakaguchi, Y.; Yamamoto, Y.; Arimitsu, H.; Tsuji, T.; Watanabe, T.; Ohyama, T.; Tomofusa, T.; Oguma, K. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum C and D neurotoxins can be used as an effective vaccine. Microbiol Immunol. 2007, 51:445–455.
   PubMed Web of Science ®Google Scholar
• Ravichandran, E.; Al-Saleem, F.H.; Ancharski, D.M.; Elias, M.D.; Singh, A.K.; Shamim, M.; Gong, Y.; Simpson, L.L. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun. 2007, 75:3043–3054.
   PubMed Web of Science ®Google Scholar
• Baldwin, M.R.; Tepp, W.H.; Przedpelski1, A.; Pier, C.L.; Bradshaw, M.; Johnson, E.A.; Barbieri, J.T. A subunit vaccine against the seven serotypes of botulism. Infect Immun. 2008, 76:1314–1318.
   PubMed Web of Science ®Google Scholar
• Smith, L.A. Development of recombinant vaccines for botulinum toxin. Toxicon. 1998, 36:1539–1548.
   PubMed Web of Science ®Google Scholar
• Byrne, M.P.; Smith, T.J.; Montgomery, V.A.; Smith, L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun. 1998, 66:4817–22.
   PubMed Web of Science ®Google Scholar
• Potter, K.J.; Bevins, M.A.; Vassilieva, E.V.; Chiruvolu, V.R.; Smith, T.; Smith, L.A.; Meagher, M.M. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype B, expressed in the methyltrophic yeast Pichia pastoris. Protein Expr Purif. 1998, 13:357–365.
   PubMed Web of Science ®Google Scholar
• Byrne, M.F.; Titball, R.W.; Holley, J.; Smith, L.A. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif. 2000, 18:327–337.
   PubMed Web of Science ®Google Scholar
• Potter, K.J.; Zhang, W.; Smith, L.A.; Meagher, M.M. Production and purification of the heavy chain fragment C of the botulinum neurotoxin, serotype A, expressed in the methyltrophic yeast Pichia pastoris. Protein Expr Purif. 2000, 19:393–402.
   PubMed Web of Science ®Google Scholar
• Boles, J.; West, M.; Montgomery, V.; Tammariello, R.; Pitt, M.L.; Gibbs, P.; Smith, L.; LeClaire, R.D. Recombinant C fragment of botulinum neurotoxin serotype B (rBoNTB(Hc)) immune response and protection in the rhesus monkey. Toxicon. 2006, 47:877–884.
   PubMed Web of Science ®Google Scholar
• Webb, R.P.; Smith, T.J.; Wright, P.M.; Montgomery, V.A.; Meagher, M.M.; Smith, L.A. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine. 2007, 25:4273–4282.
   PubMed Web of Science ®Google Scholar
• Yu, Y.Z.; Sun, Z.W.; Wang, S.; Yu, W.Y. High-level expression of the Hc domain of clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Chin J Biotech. 2007, 23:812–817.
   Google Scholar
• Yu, Y.Z.; Zhang, S.M.; Sun, Z.W.; Wang, S.; Yu, W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine. 2007, 25:8843–8850.
   PubMed Web of Science ®Google Scholar
• Romanos, M.A.; Makoff, A.J.; Fairweather, N.F.; Beesley, K.M.; Slater, D.E.; Rayment, F.B.; Payne, M.M.; Clare, J.J. Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res. 1991, 19:146–167.
   Web of Science ®Google Scholar